Profund Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Profund Advisors LLC

  • $2.65 Billion
  • Q2 2024

A detailed history of Profund Advisors LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Profund Advisors LLC holds 44,663 shares of BMRN stock, worth $3.15 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
44,663
Previous 16,158 176.41%
Holding current value
$3.15 Million
Previous $1.41 Million 160.6%
% of portfolio
0.14%
Previous 0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$74.43 - $92.22 $2.12 Million - $2.63 Million
28,505 Added 176.41%
44,663 $3.68 Million
Q1 2024

May 08, 2024
BUY
$83.81 - $99.0 $76,602 - $90,486
914 Added 6.0%
16,158 $1.41 Million
Q4 2023

Feb 14, 2024
SELL
$76.22 - $98.51 $73,399 - $94,865
-963 Reduced 5.94%
15,244 $1.47 Million
Q3 2023

Nov 13, 2023
BUY
$85.07 - $94.48 $5,529 - $6,141
65 Added 0.4%
16,207 $1.43 Million
Q2 2023

Aug 10, 2023
BUY
$86.68 - $100.3 $214,793 - $248,543
2,478 Added 18.14%
16,142 $1.4 Million
Q1 2023

May 11, 2023
SELL
$87.74 - $117.27 $619,970 - $828,629
-7,066 Reduced 34.09%
13,664 $1.33 Million
Q4 2022

Feb 02, 2023
BUY
$80.93 - $108.63 $40,869 - $54,858
505 Added 2.5%
20,730 $2.15 Million
Q3 2022

Nov 04, 2022
SELL
$82.16 - $96.94 $75,094 - $88,603
-914 Reduced 4.32%
20,225 $1.71 Million
Q2 2022

Aug 01, 2022
SELL
$71.48 - $86.85 $123,803 - $150,424
-1,732 Reduced 7.57%
21,139 $1.75 Million
Q1 2022

May 10, 2022
SELL
$74.28 - $92.69 $176,415 - $220,138
-2,375 Reduced 9.41%
22,871 $1.76 Million
Q4 2021

Feb 08, 2022
SELL
$71.72 - $91.47 $321,807 - $410,425
-4,487 Reduced 15.09%
25,246 $2.23 Million
Q3 2021

Nov 12, 2021
SELL
$74.77 - $85.47 $108,790 - $124,358
-1,455 Reduced 4.67%
29,733 $2.3 Million
Q2 2021

Aug 12, 2021
SELL
$75.51 - $84.79 $63,654 - $71,477
-843 Reduced 2.63%
31,188 $2.6 Million
Q1 2021

May 14, 2021
SELL
$74.73 - $90.69 $370,287 - $449,368
-4,955 Reduced 13.4%
32,031 $2.42 Million
Q4 2020

Feb 09, 2021
SELL
$72.61 - $90.2 $523,735 - $650,612
-7,213 Reduced 16.32%
36,986 $3.24 Million
Q3 2020

Nov 13, 2020
SELL
$71.87 - $131.03 $419,002 - $763,904
-5,830 Reduced 11.65%
44,199 $3.36 Million
Q2 2020

Aug 03, 2020
BUY
$79.55 - $124.22 $530,439 - $828,298
6,668 Added 15.38%
50,029 $6.17 Million
Q1 2020

May 15, 2020
SELL
$71.37 - $96.85 $1.04 Million - $1.4 Million
-14,505 Reduced 25.07%
43,361 $3.66 Million
Q4 2019

Feb 18, 2020
BUY
$64.27 - $86.37 $387,098 - $520,206
6,023 Added 11.62%
57,866 $4.89 Million
Q3 2019

Nov 12, 2019
SELL
$67.4 - $85.11 $177,868 - $224,605
-2,639 Reduced 4.84%
51,843 $3.49 Million
Q2 2019

Aug 13, 2019
SELL
$80.35 - $93.9 $366,315 - $428,090
-4,559 Reduced 7.72%
54,482 $4.67 Million
Q1 2019

May 15, 2019
BUY
$84.2 - $98.62 $62,897 - $73,669
747 Added 1.28%
59,041 $5.25 Million
Q4 2018

Feb 14, 2019
SELL
$80.14 - $106.07 $1.08 Million - $1.43 Million
-13,515 Reduced 18.82%
58,294 $4.96 Million
Q3 2018

Nov 13, 2018
BUY
$93.92 - $105.72 $606,441 - $682,634
6,457 Added 9.88%
71,809 $6.96 Million
Q2 2018

Aug 13, 2018
SELL
$76.01 - $99.03 $203,554 - $265,202
-2,678 Reduced 3.94%
65,352 $6.16 Million
Q1 2018

May 14, 2018
SELL
$77.67 - $92.63 $430,524 - $513,448
-5,543 Reduced 7.53%
68,030 $5.52 Million
Q4 2017

Feb 14, 2018
SELL
$80.76 - $95.13 $660,293 - $777,782
-8,176 Reduced 10.0%
73,573 $6.56 Million
Q3 2017

Nov 13, 2017
BUY
$80.6 - $94.95 $482,713 - $568,655
5,989 Added 7.91%
81,749 $7.61 Million
Q2 2017

Aug 11, 2017
BUY
N/A
75,760
75,760 $6.88 Million

Others Institutions Holding BMRN

# of Institutions
632
Shares Held
185M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email